Robert Wasserman

Stock Analyst at Benchmark

(3.30)
# 1,007
Out of 5,044 analysts
110
Total ratings
48.57%
Success rate
2.76%
Average return

Stocks Rated by Robert Wasserman

Integer Holdings
Oct 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $68.00
Upside: -
Halozyme Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $75$90
Current: $65.40
Upside: +37.61%
Intensity Therapeutics
Aug 20, 2025
Maintains: Speculative Buy
Price Target: $4$1.5
Current: $0.25
Upside: +495.47%
Bio-Techne
Jun 5, 2025
Reiterates: Buy
Price Target: $75
Current: $63.94
Upside: +17.30%
Kamada
May 15, 2025
Reiterates: Buy
Price Target: $15
Current: $6.95
Upside: +115.83%
OmniAb
May 12, 2025
Reiterates: Buy
Price Target: $6
Current: $1.55
Upside: +287.10%
XOMA Royalty
Apr 17, 2025
Initiates: Buy
Price Target: $35
Current: $34.57
Upside: +1.24%
AbCellera Biologics
Mar 3, 2025
Reiterates: Hold
Price Target: n/a
Current: $5.63
Upside: -
BioLife Solutions
Dec 19, 2024
Reiterates: Buy
Price Target: $30
Current: $28.01
Upside: +7.10%
Anebulo Pharmaceuticals
Nov 19, 2024
Reiterates: Speculative Buy
Price Target: $8
Current: $2.68
Upside: +198.51%
Reiterates: Speculative Buy
Price Target: $5
Current: $5.74
Upside: -12.89%
Maintains: Buy
Price Target: $8$12
Current: $9.47
Upside: +26.72%
Reiterates: Hold
Price Target: n/a
Current: $2.59
Upside: -
Reiterates: Hold
Price Target: n/a
Current: $151.57
Upside: -
Reiterates: Buy
Price Target: $45
Current: $53.49
Upside: -15.87%
Reiterates: Speculative Buy
Price Target: $4
Current: $4.76
Upside: -15.97%
Reiterates: Speculative Buy
Price Target: $4
Current: $0.32
Upside: +1,166.62%
Reiterates: Speculative Buy
Price Target: $75
Current: $2.56
Upside: +2,829.69%
Downgrades: Hold
Price Target: n/a
Current: $216.90
Upside: -
Initiates: Buy
Price Target: $580
Current: $557.63
Upside: +4.01%